Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tianyuan Chu
Observed names:
C. Tianyuan,
Chu, Tianyuan
Institution:
University of Essex
Observed institution:
University of Essex
ORCID:
0009-0000-2263-6163
Observed ORCID:
0009-0000-2263-6163
OpenAlex ID:
A5030956106
Fas-threshold signalling in MSCs promotes pancreatic cancer progression and metastasis
2021
·
Andrea Mohr
, Tianyuan Chu
, et al.
·
Cancer Letters
·
27
PDF
MSC.sTRAIL Has Better Efficacy than MSC.FL-TRAIL and in Combination with AKTi Blocks Pro-Metastatic Cytokine Production in Prostate Cancer Cells
2019
·
Andrea Mohr
, Tianyuan Chu
, et al.
·
Cancers
·
27
PDF
Generation of magnetic biohybrid microrobots based on MSC.sTRAIL for targeted stem cell delivery and treatment of cancer
2023
·
Rebekah Anamarie Gundersen
, Tianyuan Chu
, et al.
·
Cancer Nanotechnology
·
17
PDF
Patient-derived mesenchymal stromal cells establish an IL-6 axis that marks progression from smouldering to active multiple myeloma
2026
·
Phoebe Elizabeth Blair
, Tianyuan Chu
, et al.
·
Cytokine
PDF
MSC-delivered high-affinity variants of soluble PD1 lead to tumor regression
2026
·
Serap Gokcen
, Tianyuan Chu
, et al.
·
Cytotherapy
Fas-threshold signalling in MSCs causes tumour progression and metastasis
2021
·
A. Mohr
, C. Tianyuan
, et al.
·
Cytotherapy
Soluble trail has better efficacy than full-length membrane-bound trail, and in combination with akti blocks pro-metastatic cytokine production in prostate cancer cells
2021
·
A. Mohr
, C. Tianyuan
, et al.
·
Cytotherapy
Show more works
View as search
Works count:
13
Citation count:
71
H-index:
3
I10-index:
3
Year
Topic
Type